Everolimus in Refractory Testicular Germ Cell Cancer
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Everolimus in refractory testicular germ cell cancer. Everolimus 10 mg /day/ is administered
to the patient until progression, unacceptable toxicity, complete response or inability of
the subject to comply with study requirements. Feasibility of surgical resection will be
assessed after every 2 cycles of the treatment in patients with partial response.